Literature DB >> 19812059

Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions.

Tobias Geisler1, Christine Zürn, Rostislav Simonenko, Mathilde Rapin, Hassan Kraibooj, Antonios Kilias, Boris Bigalke, Konstantinos Stellos, Matthias Schwab, Andreas E May, Christian Herdeg, Meinrad Gawaz.   

Abstract

AIMS: Recent studies suggest a relevant association of post-interventional residual platelet aggregation (RPA) under therapy with oral platelet inhibitors and the occurrence of atherothrombotic events. The influence of post-interventional RPA on the incidence of stent thrombosis (ST) has not been sufficiently evaluated in consecutive unselected cohorts of percutaneous coronary intervention (PCI) patients. The aim of this observational study was to investigate the impact of RPA on the incidence of ST within 3 months in patients treated with dual antiplatelet therapy. METHODS AND
RESULTS: The study population included a consecutive cohort of 1019 patients treated with PCI [n = 741 bare-metal stent (BMS) and n = 278 drug-eluting stent (DES)] due to symptomatic coronary artery disease. Residual platelet activity was assessed by adenosine disphosphate (20 micromol/L)-induced PA after 600 mg clopidogrel loading dose. Maximum RPA was measured as peak of aggregation, final RPA was measured 5 min after addition of agonist. The primary endpoint was the occurrence of ST within 3 months defined according to academic research consortium (ARC) criteria. Final and maximum RPA were independent predictors of ST after 3 months. In secondary analysis, the observed effects were independently associated with early ST (HR 1.05, 95% CI 1.01-1.08 and HR 1.05, 95% CI 1.01-1.09, P < 0.01, respectively). However, incidence of 3-month late stent thrombosis (LAT) was not influenced by post-interventional RPA in multivariable analysis.
CONCLUSION: Post-interventional RPA is associated with the occurrence of early ST in patients treated with either BMS or DES; however, there is no predictive value of RPA for the incidence of 3-month LAT, suggesting the involvement of other possible mechanisms like discontinuation of antiplatelet therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812059     DOI: 10.1093/eurheartj/ehp402

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  16 in total

1.  Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.

Authors:  Patrik Htun; Suzanne Fateh-Moghadam; Christian Bischofs; Winston Banya; Karin Müller; Boris Bigalke; Konstantinos Stellos; Andreas E May; Marcus Flather; Meinrad Gawaz; Tobias Geisler
Journal:  J Am Soc Nephrol       Date:  2011-01-27       Impact factor: 10.121

Review 2.  Phagocytosis of apoptotic cells: a matter of balance.

Authors:  C J G de Almeida; R Linden
Journal:  Cell Mol Life Sci       Date:  2005-07       Impact factor: 9.261

3.  Recurrent Carotid Cavernous Fistula Originating from a Giant Cerebral Aneurysm after Placement of a Covered Stent.

Authors:  Jung Wook Baek; Sung Tae Kim; Young Seo Lee; Young-Gyun Jeong; Hae Woong Jeong; Jin Wook Baek; Jung Hwa Seo
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2016-09-30

Review 4.  Genetic determinations of variable responsiveness to clopidogrel and implications for neurointerventional procedures.

Authors:  Ruth Colley; Bernard Yan
Journal:  Interv Neurol       Date:  2012-05

Review 5.  Interventional therapies in acute myocardial infarction complicated by cardiogenic shock.

Authors:  S de Waha; S Desch; G Fuernau; J Pöss; J Ledwoch; A Jobs; I Eitel; H Thiele
Journal:  Herz       Date:  2017-02       Impact factor: 1.443

6.  Coronary stent thrombosis in the current era: challenges and opportunities for treatment.

Authors:  Bastiaan Zwart; Jochem W van Werkum; Antonius A C M Heestermans; Jurriën M Ten Berg
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-01

7.  Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation.

Authors:  Philipp Diehl; Christoph Halscheid; Christoph Olivier; Thomas Helbing; Christoph Bode; Martin Moser
Journal:  Clin Res Cardiol       Date:  2011-04-09       Impact factor: 5.460

8.  Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China.

Authors:  Hui-Hui Lv; Shuai Wu; Xu Liu; Xiao-Li Yang; Jian-Feng Xu; Yang-Tai Guan; Qiang Dong; S Lilly Zheng; Jian-Ming Jiang; Shi-Xu Li; Zheng Luo; Li Li; Li-Xian An; Yan Han
Journal:  Neurol Sci       Date:  2015-10-31       Impact factor: 3.307

9.  Influence of HbA1c levels on platelet function profiles associated with tight glycemic control in patients presenting with hyperglycemia and an acute coronary syndrome. A subanalysis of the CHIPS Study ("Control de HIperglucemia y Actividad Plaquetaria en Pacientes con Síndrome Coronario Agudo").

Authors:  David Vivas; Juan C García-Rubira; Esther Bernardo; Dominick J Angiolillo; Patricia Martín; Alfonso Calle-Pascual; Iván Núñez-Gil; Carlos Macaya; Antonio Fernández-Ortiz
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

10.  Towards personalized medicine based on platelet function testing for stent thrombosis patients.

Authors:  Thea Cornelia Godschalk; Christian Marcus Hackeng; Jurriën Maria Ten Berg
Journal:  Thrombosis       Date:  2012-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.